Roche’s Tecentriq receives NICE approval for lung cancer

Roche has announced that its lung cancer therapy Tecentriq has been approved for the most common form of the disease by the National Institute for Health and Care Excellence (NICE).

Patients with advanced non-small-cell lung cancer (NSCLC) whose disease has progressed following standard chemotherapy will now be able to access the immunotherapy via the NHS in England and Wales following this regulatory decision.

NICE had previously decided against approving Tecentriq in this indication, but has been persuaded to reverse the decision based on positive data from a phase III study showing how the drug is able to deliver survival benefits for people with NSCLC.

Tecentriq is classed as a programmed death ligand 1 (PD-L1) inhibitor therapy, but has also been shown to be an effective option for patients regardless of PD-L1 expression.

Simon Eayrs, integrated franchise lead at Roche Products, said: "We are delighted that NICE has revised its decision, meaning that people living with this devastating form of cancer will now have access to a much-needed treatment."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.